Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register

Abstract

Contributors NE, AG, RN and RMM made a substantial contribution to the work. AG, WJR, TF, EMC, KAT-D and DVF acquired, analysed and interpreted data. AC, Rd, RH, SH, OP, DR, ECT and MD revised it critically for important intellectual content.

COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review

“…Overall, 379 MS patients with COVID-19 were reported who did not receive any medications. ( Bowen et al, 2020 , Louapre et al, 2020 , Parrotta et al, 2020 , Barzegar et al, 2020 , Mantero et al, 2020 , Sahraian et al, 2020 , Nesbitt et al, 2020 , Chaudhry et al, 2020 , Castillo Álvarez et al, 2020 , Crescenzo et al, 2020 , Sormani et al, 2020 , Evangelou et al, 2020 , Loonstra et al, 2020 ). In this group, 14(3.6%) patients died.…”

“… Confirmed patients Death Suspicious patients TotalPatients TotalDeath (%) Interferon beta ( Safavi et al, 2020 , Bowen et al, 2020 , Louapre et al, 2020 , Parrotta et al, 2020 , Barzegar et al, 2020 , Ciampi et al, 2020 , Mantero et al, 2020 , Sahraian et al, 2020 , Chaudhry et al, 2020 , Castillo Álvarez et al, 2020 , Sormani et al, 2020 , Evangelou et al, 2020 , Loonstra et al, 2020 ) 61 74 135 0 Interferons/GA ( Dalla Costa et al, 2020 , Nesbitt et al, 2020 ) - - 84 84 0 GA ( Bowen et al, 2020 , Louapre et al, 2020 , Parrotta et al, 2020 , Sahraian et al, 2020 , Maillart et al, 2020 , Chaudhry et al, 2020 , Sormani et al, 2020 , Evangelou et al, 2020 , Loonstra et al, 2020 , Kataria et al, 2020 ) 67 1-71 -year-old,Male, SPMS Comorbidities: Venus Thrombo embli and obesity ( Parrotta et al, 2020 ) 2-64 -year-old, Male, RRMS, EDSS: 2, no comorbidity. ( Sormani et al, 2020 ) 73 140 2(1.4%) DMF ( Louapre et al, 2020 , Parrotta et al, 2020 , Barzegar et al, 2020 , Ciampi et al, 2020 , Mantero et al, 2020 ...…”

“…( Sormani et al, 2020 ) 73 140 2(1.4%) DMF ( Louapre et al, 2020 , Parrotta et al, 2020 , Barzegar et al, 2020 , Ciampi et al, 2020 , Mantero et al, 2020 , Sahraian et al, 2020 , Nesbitt et al, 2020 , Chaudhry et al, 2020 , Castillo Álvarez et al, 2020 , Mantero et al, 2020 , Crescenzo et al, 2020 , Sormani et al, 2020 , Evangelou et al, 2020 , Loonstra et al, 2020 , Kataria et al, 2020 ) 119 1-68 -year-old,Male, SPMS, EDSS:6 Comorbidities: cerebrovascular disease, Hypertension ( Sormani et al, 2020 ) 195 314 1(0.3%) DMF/Teriflunomide ( Nesbitt et al, 2020 , Dalla Costa et al, 2020 ) 108 108 0 Teriflunomide ( Safavi et al, 2020 , Bowen et al, 2020 , Louapre et al, 2020 , Ciampi et al, 2020 , Mantero et al, 2020 , Sahraian et al, 2020 , Nesbitt et al, 2020 , Chaudhry et al, 2020 , Castillo Álvarez et al, 2020 , Maillart et al, 2020 , Crescenzo et al, 2020 , Maghzi et al, 2020 , Möhn et al, 2020 , Bollo et al, 2020 , Ciardi et al, 2020 , Valencia-Sanchez and Wingerchuk, 2020 , Sormani et al, 2020 , Evangelou et al, 2020 , …”

“…( Rimmer et al, 2020 ) 3-52 -year-old Female, RRMS,EDSS:5, no Comorbidity . ( Sormani et al, 2020 ) 136 233 3(1.2%) Alemtuzumab ( Louapre et al, 2020 , Ciampi et al, 2020 , Nesbitt et al, 2020 , Chaudhry et al, 2020 , Castillo Álvarez et al, 2020 , Carandini et al, 2020 , Matías-Guiu et al, 2020 , Guevara et al, 2020 , Fernández-Díaz et al, 2020 , Fiorella and Lorna, 2020 , Sormani et al, 2020 , Evangelou et al, 2020 , Loonstra et al, 2020 ) 14 23 37 0 Alemtuzumab/ Cladribine ( Dalla Costa et al, 2020 ) 15 15 0 Cladribine ( Louapre et al, 2020 , Nesbitt et al, 2020 , Castillo Álvarez et al, 2020 , Dersch et al, 2020 , De Angelis et al, 2020 , Celius, 2020 , Jack et al, 2020 , Sormani et al, 2020 , Evangelou et al, 2020 , Loonstra et al, 2020 , Preziosa et al, 2020 ) 35 56 91 0 Ocrelizumab ( Louapre et al, 2020 , Parrotta et al, 2020 , Ciampi et al, 2020 , Sahraian et al, 2020 , Chaudhry et al, 2020 , Maillart et al, 2020 , Ciampi et al, 2020 , Crescenzo et al, 2020 , ...…”

Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era

“…The current state of the evidence suggests that simply having MS does not increase risk of SARS-CoV-2 infection or worsen clinical outcomes compared to those without MS ( Evangelou et al., 2020 ; Parrotta et al., 2020 ). As with the general population, PwMS with risk factors such as older age, obesity, diabetes, cardiac and pulmonary comorbidities, and potentially physical disability may be at higher risk for more severe outcomes of COVID-19 if they become infected ( Louapre et al., 2020 ; Multiple Sclerosis International Federation, 2020 ; Sormani et al., 2020 ).…”